Yong Ju , Joshua Watson , Jasmine J. Wang , Ying-Tzu Yen , Lilit Gevorkian , Zijing Chen , Kai Han Tu , Brenda Salumbides , Aaron Phung , Chen Zhao , Hyoyong Kim , You-Ren Ji , Ryan Y. Zhang , Junseok Lee , Jun Gong , Kevin Scher , Sungyong You , Jie-Fu Chen , Hsian-Rong Tseng , Yazhen Zhu , Edwin M. Posadas
{"title":"B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer","authors":"Yong Ju , Joshua Watson , Jasmine J. Wang , Ying-Tzu Yen , Lilit Gevorkian , Zijing Chen , Kai Han Tu , Brenda Salumbides , Aaron Phung , Chen Zhao , Hyoyong Kim , You-Ren Ji , Ryan Y. Zhang , Junseok Lee , Jun Gong , Kevin Scher , Sungyong You , Jie-Fu Chen , Hsian-Rong Tseng , Yazhen Zhu , Edwin M. Posadas","doi":"10.1016/j.drup.2025.101207","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>B7-H3 is a promising target for cancer therapy, notably in prostate cancer (PCa), particularly in metastatic, castration-resistant PCa (mCRPC). With the development of B7-H3-targeted therapies, there is a need for a rapid, reliable, and cost-effective method to detect and monitor B7-H3 expression. Leveraging their abundance and stability, we developed a liquid biopsy assay using extracellular vesicles (EVs) for this purpose.</div></div><div><h3>Methods</h3><div>B7-H3<sup>+</sup> EVs were isolated using a B7-H3 antibody-mediated, click chemistry-based enrichment method. Antibodies were conjugated to methyltetrazine-grafted microbeads. EVs were isolated from 100 µL of plasma from metastatic, castration-sensitive PCa (mCSPC) (n = 43) and mCRPC (n = 103) patients and quantified using RT-qPCR of <em>ACTB</em>. Measurements were compared with the patient's disease status over time.</div></div><div><h3>Results</h3><div>The assay detected higher B7-H3<sup>+</sup> EVs in mCRPC than mCSPC and increased when mCSPC transitioned to mCRPC. Elevated B7-H3<sup>+</sup> EVs were associated with lower overall survival (Hazard ratio (HR) 2.19, <em>p</em> = 0.01). In patients with serial plasma samples, B7-H3<sup>+</sup> EV levels reflected treatment response and disease progression.</div></div><div><h3>Conclusions</h3><div>This B7-H3<sup>+</sup> EV assay represents a significant advancement in utilizing tumor-derived EVs for a non-invasive, quantitative, and consistent real-time measurement of B7-H3. This assay warrants further development as a companion diagnostic for B7-H3 targeted therapies in PCa and other conditions.</div></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"79 ","pages":"Article 101207"},"PeriodicalIF":15.8000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Resistance Updates","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S136876462500007X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
B7-H3 is a promising target for cancer therapy, notably in prostate cancer (PCa), particularly in metastatic, castration-resistant PCa (mCRPC). With the development of B7-H3-targeted therapies, there is a need for a rapid, reliable, and cost-effective method to detect and monitor B7-H3 expression. Leveraging their abundance and stability, we developed a liquid biopsy assay using extracellular vesicles (EVs) for this purpose.
Methods
B7-H3+ EVs were isolated using a B7-H3 antibody-mediated, click chemistry-based enrichment method. Antibodies were conjugated to methyltetrazine-grafted microbeads. EVs were isolated from 100 µL of plasma from metastatic, castration-sensitive PCa (mCSPC) (n = 43) and mCRPC (n = 103) patients and quantified using RT-qPCR of ACTB. Measurements were compared with the patient's disease status over time.
Results
The assay detected higher B7-H3+ EVs in mCRPC than mCSPC and increased when mCSPC transitioned to mCRPC. Elevated B7-H3+ EVs were associated with lower overall survival (Hazard ratio (HR) 2.19, p = 0.01). In patients with serial plasma samples, B7-H3+ EV levels reflected treatment response and disease progression.
Conclusions
This B7-H3+ EV assay represents a significant advancement in utilizing tumor-derived EVs for a non-invasive, quantitative, and consistent real-time measurement of B7-H3. This assay warrants further development as a companion diagnostic for B7-H3 targeted therapies in PCa and other conditions.
期刊介绍：
Drug Resistance Updates serves as a platform for publishing original research, commentary, and expert reviews on significant advancements in drug resistance related to infectious diseases and cancer. It encompasses diverse disciplines such as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The journal addresses both basic research and clinical aspects of drug resistance, providing insights into novel drugs and strategies to overcome resistance. Original research articles are welcomed, and review articles are authored by leaders in the field by invitation.
Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective.
*Expert reviews in clinical and basic drug resistance research in oncology and infectious disease
*Describes emerging technologies and therapies, particularly those that overcome drug resistance
*Emphasises common themes in microbial and cancer research
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
